LongeVC managing partner Sergey Jakimov and operating partner Artem Trotsyuk have co-authored a piece for Pharmaphorum making the case that longevity science is being held back by its association with consumer wellness culture, and that pharma must take the lead in changing that.
In the article, Sergey and Artem argue that real progress in longevity will not come from supplements, clinics, or lifestyle optimization. It will come from rigorous drug development: clear disease indications, validated biomarkers, defined regulatory pathways, and measurable clinical endpoints.
Read the full piece here.
In the article, Sergey and Artem argue that real progress in longevity will not come from supplements, clinics, or lifestyle optimization. It will come from rigorous drug development: clear disease indications, validated biomarkers, defined regulatory pathways, and measurable clinical endpoints.
Read the full piece here.